JP2013526507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526507A5 JP2013526507A5 JP2013509548A JP2013509548A JP2013526507A5 JP 2013526507 A5 JP2013526507 A5 JP 2013526507A5 JP 2013509548 A JP2013509548 A JP 2013509548A JP 2013509548 A JP2013509548 A JP 2013509548A JP 2013526507 A5 JP2013526507 A5 JP 2013526507A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- pain
- hereinafter
- disorders
- inflammatory diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 22
- 239000003814 drug Substances 0.000 description 18
- 208000027866 inflammatory disease Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 208000004296 neuralgia Diseases 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 206010065390 Inflammatory pain Diseases 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000015879 Cerebellar disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 208000027520 Somatoform disease Diseases 0.000 description 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000018254 acute transverse myelitis Diseases 0.000 description 2
- 208000018300 basal ganglia disease Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000025434 cerebellar degeneration Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000027753 pain disease Diseases 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000009174 transverse myelitis Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 206010024626 Lipoprotein deficiency Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 210000002226 anterior horn cell Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002594 corticospinal effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10162629 | 2010-05-12 | ||
| EP10162629.9 | 2010-05-12 | ||
| PCT/EP2011/057545 WO2011141474A1 (en) | 2010-05-12 | 2011-05-10 | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015120556A Division JP5796266B1 (ja) | 2010-05-12 | 2015-06-15 | 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013526507A JP2013526507A (ja) | 2013-06-24 |
| JP2013526507A5 true JP2013526507A5 (enExample) | 2014-11-06 |
Family
ID=42782240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509548A Withdrawn JP2013526507A (ja) | 2010-05-12 | 2011-05-10 | 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
| JP2015120556A Active JP5796266B1 (ja) | 2010-05-12 | 2015-06-15 | 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015120556A Active JP5796266B1 (ja) | 2010-05-12 | 2015-06-15 | 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8877745B2 (enExample) |
| EP (1) | EP2569298B1 (enExample) |
| JP (2) | JP2013526507A (enExample) |
| WO (1) | WO2011141474A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5603770B2 (ja) | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２受容体拮抗薬およびその使用 |
| CN102256963B (zh) | 2008-12-19 | 2014-06-11 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| ES2674275T3 (es) | 2009-12-17 | 2018-06-28 | Centrexion Therapeutics Corporation | Antagonistas del receptor CCR2 y usos de los mismos |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| JP5646736B2 (ja) | 2010-05-12 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用 |
| WO2011144501A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| EP3255041A1 (en) * | 2011-09-02 | 2017-12-13 | Purdue Pharma L.P. | Pyrimidines as sodium channel blockers |
| DK3071559T3 (en) | 2013-11-18 | 2018-02-12 | Elanco Tiergesundheit Ag | (Hetero) arylamides for the control of endoparasites |
| AU2015217185B2 (en) * | 2014-02-12 | 2018-04-05 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
| JP6621477B2 (ja) * | 2014-12-18 | 2019-12-18 | ファイザー・インク | ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用 |
| DK3297438T3 (da) | 2015-05-21 | 2022-01-17 | Chemocentryx Inc | Ccr2-modulatorer |
| PT3317270T (pt) | 2015-07-02 | 2020-08-24 | Centrexion Therapeutics Corp | (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidina-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-pirano-2-il)metilamino)pirimidina-4-il)citrato de metanona |
| CN105560234A (zh) * | 2016-02-18 | 2016-05-11 | 郑海英 | 一种治疗口腔颌面炎症的药物组合物 |
| CA3293051A1 (en) | 2017-09-25 | 2026-03-02 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| CN112105353B (zh) | 2018-01-08 | 2024-04-19 | 凯莫森特里克斯股份有限公司 | Ccr2拮抗剂治疗实体瘤的方法 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| CN110872302B (zh) * | 2018-08-31 | 2022-09-27 | 沈阳中化农药化工研发有限公司 | 含嘧啶的螺环类化合物及其用途 |
| WO2024015761A2 (en) * | 2022-07-11 | 2024-01-18 | Rutgers, The State University Of New Jersey | Gαlpha12 inhibitors and methods using same |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4032526A (en) | 1975-10-02 | 1977-06-28 | American Cyanamid Company | 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts |
| US4426382A (en) | 1980-02-13 | 1984-01-17 | Sankyo Company Limited | 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use |
| DE3517617A1 (de) | 1985-05-15 | 1986-11-20 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel |
| DE69325662T2 (de) | 1992-10-23 | 2000-02-10 | Merck Sharp & Dohme Ltd., Hoddesdon | Dopamin rezeptor subtyp liganden |
| US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
| EE04588B1 (et) | 1997-10-27 | 2006-02-15 | Neurosearch A/S | Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon |
| US6143892A (en) | 1998-11-20 | 2000-11-07 | G. D. Searle & Co. | Process for making 5-substituted pyrazoles |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| SK287418B6 (sk) | 1999-05-04 | 2010-09-07 | Schering Corporation | Farmaceutický prípravok s obsahom CCR5 antagonistov a súprava s obsahom tohto prípravku |
| GB0004153D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| OA12274A (en) | 2000-05-22 | 2006-05-09 | Aventis Pharma Inc | Arylmethylamine derivatives for use as tryptase inhibitors. |
| WO2002030928A1 (de) | 2000-10-12 | 2002-04-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kristallines monohydrat, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels |
| AR035700A1 (es) | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| ME00412B (me) | 2001-06-22 | 2011-10-10 | Boehringer Ingelheim Pharma | Kristalni antiholinergik , postupak za njegovo pripremanje i njegova primjena u proizvodnji lijeka |
| WO2003037271A2 (en) | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| US6806279B2 (en) | 2001-12-17 | 2004-10-19 | Sunesis Pharmaceuticals, Inc. | Small-molecule inhibitors of interleukin-2 |
| EP1474401A2 (en) | 2002-02-05 | 2004-11-10 | Novo Nordisk A/S | Novel aryl- and heteroarylpiperazines |
| HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| CN100445276C (zh) | 2002-03-13 | 2008-12-24 | 詹森药业有限公司 | 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物 |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| TW200400960A (en) | 2002-06-05 | 2004-01-16 | Pharmacia Corp | Novel pyrazoles and their use as P38 kinase inhibitors |
| AU2003270199A1 (en) | 2002-09-13 | 2004-04-30 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
| GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| WO2004074438A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| CA2523431A1 (en) | 2003-04-23 | 2004-11-25 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| FR2854158B1 (fr) | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| JP2006528147A (ja) | 2003-07-18 | 2006-12-14 | グラクソ グループ リミテッド | ヒスタミンｈ３受容体リガンドとしての置換ピペリジン |
| WO2005009976A1 (en) | 2003-07-29 | 2005-02-03 | Novo Nordisk A/S | Pyridazinyl- piperazines and their use as histamine h3 receptor ligands |
| KR20080052683A (ko) | 2003-12-18 | 2008-06-11 | 인사이트 코포레이션 | 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체 |
| US7435830B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7423147B2 (en) | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2006001958A2 (en) | 2004-05-21 | 2006-01-05 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| CA2569016C (en) | 2004-06-02 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US8071624B2 (en) | 2004-06-24 | 2011-12-06 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| WO2006012135A1 (en) | 2004-06-24 | 2006-02-02 | Janssen Pharmaceutica, N. V. | Quaternary salt ccr2 antagonists |
| WO2006004741A2 (en) | 2004-06-28 | 2006-01-12 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
| CA2589106C (en) | 2004-11-02 | 2015-07-21 | Northwestern University | Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases |
| DE102004061751A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Cyanoguanidin-substituierte Pyrazoline |
| TWI385164B (zh) | 2005-02-17 | 2013-02-11 | Astellas Pharma Inc | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II) |
| JP2008537953A (ja) | 2005-04-15 | 2008-10-02 | エラン ファーマシューティカルズ，インコーポレイテッド | ブラジキニンｂ１受容体拮抗作用に有用な新規化合物 |
| TW200716594A (en) | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
| EP2354140A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| MX2007015675A (es) | 2005-07-04 | 2008-02-20 | Novo Nordisk As | Antagonistas del receptor de histamina h3. |
| US7851474B2 (en) | 2005-08-02 | 2010-12-14 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| GB0517184D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| KR101415426B1 (ko) | 2005-09-27 | 2014-07-04 | 아이알엠 엘엘씨 | 디아릴아민-함유 화합물 및 조성물, 및 ｃ-ｋｉｔ 수용체의조절제로서의 그의 용도 |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| WO2007053495A2 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| CN101309915A (zh) | 2005-11-14 | 2008-11-19 | Irm责任有限公司 | 作为lxr调节剂的化合物和组合物 |
| WO2007084868A2 (en) | 2006-01-17 | 2007-07-26 | Kalypsys, Inc. | Treatment of disorders by activation of the unfolded protein response |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| NZ570847A (en) | 2006-02-28 | 2011-10-28 | Helicon Therapeutics Inc | Therapeutic compounds |
| WO2007105058A2 (en) | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
| EA200870404A1 (ru) | 2006-04-03 | 2009-04-28 | Глэксо Груп Лимитед | Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3 |
| WO2007120574A2 (en) | 2006-04-11 | 2007-10-25 | Merck & Co., Inc. | Diaryl substituted alkanes |
| US7807671B2 (en) | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| US20100168120A1 (en) | 2006-04-28 | 2010-07-01 | Neuromedix Inc. | Salts of pyridazine compounds |
| US20080039450A1 (en) | 2006-06-22 | 2008-02-14 | Jensen Annika J | Compounds |
| GB0617867D0 (en) | 2006-09-11 | 2006-10-18 | Glaxo Group Ltd | Chemical compounds |
| ES2548353T3 (es) | 2006-12-28 | 2015-10-15 | Abbvie Inc. | Inhibidores de poli(ADP-ribosa)polimerasa |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| JP5603770B2 (ja) * | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２受容体拮抗薬およびその使用 |
| DE102007027808B3 (de) * | 2007-06-13 | 2008-08-14 | Gressel Ag | Spannvorrichtung |
| MX2010002005A (es) | 2007-08-22 | 2010-03-11 | Irm Llc | Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa. |
| RU2010116821A (ru) | 2007-10-01 | 2011-11-10 | Ф.Хоффманн-Ля Аг (Ch) | N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr |
| RU2487127C2 (ru) | 2007-10-09 | 2013-07-10 | Ф.Хоффманн-Ля Рош Аг | Хиральные цис-имидазолины |
| US20090131417A1 (en) | 2007-11-20 | 2009-05-21 | Letavic Michael A | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| EP2062889A1 (de) | 2007-11-22 | 2009-05-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbindungen |
| US8829006B2 (en) * | 2007-11-22 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Compounds |
| AU2009259496A1 (en) | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Novel heteroaryl carboxamide derivatives |
| JP5693452B2 (ja) | 2008-08-04 | 2015-04-01 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法 |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| AU2009289378A1 (en) | 2008-09-02 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Novel benzamides, production thereof, and use thereof as medicaments |
| CN102256963B (zh) | 2008-12-19 | 2014-06-11 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| US20110301143A1 (en) | 2009-02-23 | 2011-12-08 | Elise Isabel | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP2513086B1 (en) | 2009-12-17 | 2015-04-29 | Boehringer Ingelheim International GmbH | Novel antagonists for ccr2 and uses thereof |
| ES2674275T3 (es) | 2009-12-17 | 2018-06-28 | Centrexion Therapeutics Corporation | Antagonistas del receptor CCR2 y usos de los mismos |
| JP5646736B2 (ja) | 2010-05-12 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用 |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011144501A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
| WO2012171863A1 (en) | 2011-06-16 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
-
2011
- 2011-05-10 WO PCT/EP2011/057545 patent/WO2011141474A1/en not_active Ceased
- 2011-05-10 US US13/696,859 patent/US8877745B2/en active Active
- 2011-05-10 JP JP2013509548A patent/JP2013526507A/ja not_active Withdrawn
- 2011-05-10 EP EP11719249.2A patent/EP2569298B1/en active Active
-
2015
- 2015-06-15 JP JP2015120556A patent/JP5796266B1/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013526507A5 (enExample) | ||
| JP2013528597A5 (enExample) | ||
| JP2013526596A5 (enExample) | ||
| JP2013530953A5 (enExample) | ||
| JP2013526554A5 (enExample) | ||
| JP2023508469A5 (enExample) | ||
| WO2007036745A3 (en) | Interleukin-13 antibody composition | |
| WO2018144551A3 (en) | D-methadone and its derivatives for use in the treatment of disorders of the nervous system | |
| MX2010004614A (es) | Composiciones para tratamiento del mal de parkinson. | |
| WO2008132723A3 (en) | Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system | |
| Khan et al. | Nature's toolbox against tau aggregation: an updated review of current research | |
| MX356669B (es) | Terapia genica para trastornos neurodegenerativos. | |
| WO2009050242A3 (de) | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine | |
| WO2009005794A3 (en) | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | |
| WO2008008359A3 (en) | Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor | |
| MX2011011233A (es) | Una formulacion novedosa de metaxalona. | |
| WO2007009083A3 (en) | Compounds with activity at retinoic acid receptors | |
| ME02481B (me) | Hirohloridna so 4-[2-[[5-metil-1-(2-naftalenii)-1H-pirazol-3-il]oksl]ethll]morfolina | |
| WO2006108582A3 (en) | Human marker genes and agents for diagnosis, treatment and prophylaxis of cardiovascular disorders and artherosclerosis | |
| JP2013523623A5 (enExample) | ||
| IL204064A (en) | Compounds 4-Formylphiprazine-1-Carboxamidine Efficacy as Muscarinic Receptor Antagonists | |
| HK1206350A1 (en) | 2h-imidazol-4-amine compounds and their use as bace inhibitors | |
| WO2008064136A3 (en) | Compounds with activity at retinoic acid receptors | |
| EP4501362A3 (en) | Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production | |
| HK1206347A1 (en) | Cyclohexane-1,2'-naphthalene-1',2"-imidazole compounds and their use as bace inhibitors |